UW Bioengineering
Fast Facts
News and Events
BioEngage hosts fall mixer, launches industry job & internship program
This fall, UW BioEngage continued its mission of connecting UW Bioengineering trainees and faculty with the biotech and medical device industries.
Events
UW BioE students receive scholarships and fellowships
We are proud of our students who have been [...]
In Memoriam: Allan Hoffman, October 27, 1932 – December 15, 2023
Recognized as the international “ambassador for biomaterials,” Professor Emeritus [...]
UW BioE rowers share their musings about rowing and bioengineering
Teamwork, resilience and excellence UW BioE rowers share their [...]
Featured Publications
Desktop-Stereolithography 3D-Printing of a Poly(dimethylsiloxane)-Based Material with Sylgard-184 Properties
Professor Albert Folch's lab reports on the formulation, characterization, and SL application of a 3D?printable PDMS resin (3DP?PDMS) based on commercially available PDMS?methacrylate macromers, a high?efficiency photoinitiator and a high?absorbance photosensitizer. 3DP?PDMS resin enables assembly?free, automated, digital manufacturing of PDMS, which should facilitate the prototyping of devices for microfluidics, organ?on?chip platforms, soft robotics, flexible electronics, and sensors, among others.
Chitosan enhances nanoparticle delivery from the reproductive tract to target draining lymphoid organs
The researchers propose a method to achieve enhanced immune response against viral infections in the female reproductive tract. They demonstrate that intravaginal pre-treatment with chitosan significantly facilitates translocation of nanoparticles across the the multilayered vaginal epithelium to target draining lymph nodes.
Synthetic Macromolecular Antibiotic Platform for Inhalable Therapy against Aerosolized Intracellular Alveolar Infections
The researchers demonstrate a macromolecular therapeutic platform that provides sustained local delivery of ciprofloxacin. Their work addresses the unmet need for inhaled treatments for lung-based intracellular bacterial infections such as Franciscella tularensis pneumonia (tularemia), which are currently treated with oral or IV antibiotics that poorly achieve and sustain pulmonary drug bioavailability.
